# Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

> **NCT00596752** · PHASE4 · COMPLETED · sponsor: **UCB BIOSCIENCES GmbH** · enrollment: 840 (actual)

## Conditions studied

- Peripheral Arterial Occlusive Disease

## Interventions

- **DRUG:** Alprostadil
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00596752
- **Lead sponsor:** UCB BIOSCIENCES GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-07
- **Target enrollment:** 840 (ACTUAL)
- **Last updated:** 2018-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00596752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00596752, "Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00596752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*